February 21, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced its

February 8, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its in

Company's Overseas Delivery of Varicella Vaccine and Approval to Expand Use of CoronaVac Will Help Turkish Minors Combat Infectious DiseasesFebruary 3, 2023, Beijing -- Sinovac Biotech Ltd. ("

January 12, 2023, Beijing, China – January 12, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical produ

January 6, 2023, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that a recen

BEIJING, China, December 29, 2022 -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its

December 20, 2022, Hong Kong -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID

December 6, 2022, Jakarta -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its inactiva

November 29, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its quadriv

November 22, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-1

November 18, 2022, Jakarta -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China,

November 9, 2022, Islamabad -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Compan

November 4, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it rec

October 28th, 2022, Beijing -- Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate i

On September 24, the handover ceremony of the Chinese government's donation of COVID-19 vaccine to Egyptian women, children, and adolescents & the delivery ceremony of SINOVAC's sponsored

October 21, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that the Co

SINOVAC's quadrivalent influenza vaccine collaborated with a local partner has been approved by the Directorate General of Drug Administration (DGDA) in Bangladesh for marketing use recently. This

September 6, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean

August 25, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean P

August 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Qual

August 3, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on relat

July 19, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III cli

July 14, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 va

HONG KONG--A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific C

Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products R

BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received the World Heal

On May 20, 2022, the Public Health Institute of Chile (ISP) released the fourth statistical report "AEFIs after the administration of SARS-CoV-2 vaccines in Chile in the pediatric and adolescent

May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the "MITRA BUMN GLOBAL CHAMPION 2022" awa

BEIJING, China--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S.

April 26, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in China. SINOVAC continuously carried out the de

April 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China. SINOVAC continuously carrie

A study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of

The inactivated COVID-19 vaccine CoronaVac®, innovated and manufactured by Sinovac Biotech LTD. (SINOVAC), has been widely used in Chilean minors since September 2021. Recently, an interim safety and

On Mar. 15, 2022, a real-world study report accessed the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in children 3 to 5 years old in Chile during the prevalence of Omicron was recen

Real-world data show effectiveness of CoronaVac® 74.5% for prevent of COVID-19, 91.0% for hospitalisation and 93.8% for ICU admission in children and adolescents aged 6 to 16 years old· 95% of indivi

During the past two years, the covid-19 pandemic affected almost all people in the world, and every aspect of people’s lives has been affected. The elderly, those were considered the most vulnerable p

Represented by: Professor Rocky S. TUAN, Vice-Chancellor and President of CUHK, Mr. Weidong YIN, Chairman, President, and CEO of SINOVAC Biotech Limited Witnessed by:Professor Wai Yee CHAN, Pro-Vice-C

Developing the city into high ground for biomedical sciencesThe Chinese University of Hong Kong (CUHK) and Sinovac Biotech (Hong Kong) Limited (SINOVAC) signed a new Strategic Collaboration Framework

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results

SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, collaborating with IQVIA Brazil published an article on December 17 titled “

Beijing, China, December 24, 2021 – SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced resu

Current SINOVAC Directors Elected Properly at the 2018 Annual General Meeting The Company's Rights Agreement is Valid under Antigua LawDecember 9, 2021 -- BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SV

Instituto Butantan, in partnership with Sinovac Biotech, is pleased to announce CoronaVac® Symposium, an international online event that aims to promote and discuss the latest results of the efficacy

Beijing，November 18, 2021, the 2nd International Conference on the Latest Researches and Experience Sharing on SINOVAC's COVID-19 Vaccine hosted by SINOVAC Biotech Ltd (SIONVAC). was held successf

Yangon, Myanmar- 8 November, 2021Sea Lion Group is pleased to announce a collaboration with Sinovac Biotech Ltd. (SINOVAC) to facilitate the c

The Egyptian delegation led by H.E. Ambassador to China Dr. Mohamed Elbadri visited the production base of Sinovac Life Sciences in Daxing, Beijing on 21 October 2021, accompanied by Chairman Weidong

· Doses will be available through SGX-Catalist listed Livingstone Health group at 17 clinics islandwide· Inactivated viral vaccines offer an alternative option for those unable to take up vaccines ava

Study findings demonstrate that a booster dose of inactivated COVID-19 vaccine produces a highly sifted, humoral immune response via a sustained evolution of antibodies, able to effectively neutralize

BEIJING, China, Sep 9, 2021 – SINOVAC Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Coron

CoronaVac® generates good immune memory after second doseThird dose of vaccine significantly increased neutralizing antibody levels in adults and elderly populationFindings indicate a third dose of Co

CoronaVac® generates good immune memory after the second doseThird dose of CoronaVac® induces strong immune response No serious adverse reactions reportedAdverse reactions reported within 28 day after

BEIJING, China, July 19, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced CoronaV

SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it received a drug registration approval

SINOVAC Biotech Ltd. ("SINOVAC") recently noticed a Portuguese-language press release with a statement that does not conform to the facts. This fraudulent statement ("Fraudulent Stateme

BEIJING, China, July 12, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it

The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3

BEIJING – June 12, 2021 – SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Inlive®, an innovative, inact

BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, in

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securit

Project Title:A Phase III Clinical Trial of the 5-Dose Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin StrainProtocol Title:A clinical trial with an open-label phase to evaluate the safety of Sa

Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in The Journal of Infectious DiseasesThe Sinovac-developed sIPV demonstrates

BEIJING, Aug.12, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2015.

sinovac

Sinovac Receives GMP Certificate in Mexico for Seasonal Flu Vaccine and Hepatitis A Vaccine

Sinovac

Sinovac Participates in Two Investor Conferences in November